Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria

Summary

Based upon the preclinical evidence in models of diabetic nephropathy under conditions approximating both type I and II diabetes, treatment with alagebrium appears to have favorable and advantageous effects on the biochemical, structural, pathological and functional hallmarks of diabetic nephropathy. The renoprotective effects of alagebrium in preclinical models favor the evaluation of this drug in patients with type I diabetes.

Timeline

Start

2007-11

Primary completion

2009-09

Completion

2009-11

Outcome

Outcome not reported

Stopped (Business): “Study has been terminated early due to financial constraints.”

Drugs

Indications